These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18164510)

  • 21. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
    J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis.
    Norum J; Olsen JA; Wist EA; Lønning PE
    Acta Oncol; 2007; 46(2):153-64. PubMed ID: 17453363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.
    Danese MD; Lalla D; Brammer M; Doan Q; Knopf K
    Cancer; 2010 Dec; 116(24):5575-83. PubMed ID: 20734398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
    Poncet B; Bachelot T; Colin C; Ganne C; Jaisson-Hot I; Orfeuvre H; Peaud PY; Jacquin JP; Salles B; Tigaud JD; Mechin-Cretinon I; Marechal F; Fournel C; Trillet-Lenoir V
    Am J Clin Oncol; 2008 Aug; 31(4):363-8. PubMed ID: 18845995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Facts and controversies in the use of trastuzumab in the adjuvant setting.
    Dinh P; de Azambuja E; Cardoso F; Piccart-Gebhart MJ
    Nat Clin Pract Oncol; 2008 Nov; 5(11):645-54. PubMed ID: 18779850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
    Benjamin L; Buthion V; Iskedjian M; Farah B; Rioufol C; Vidal-Trécan G
    J Med Econ; 2013; 16(1):96-107. PubMed ID: 22970840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab for early breast cancer: current status and future directions.
    Dinh P; de Azambuja E; Piccart-Gebhart MJ
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):707-17. PubMed ID: 17982412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
    Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
    BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Candon D; Healy J; Crown J
    Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
    Dedes KJ; Szucs TD; Imesch P; Fedier A; Fehr MK; Fink D
    Ann Oncol; 2007 Sep; 18(9):1493-9. PubMed ID: 17761705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.
    Poncet B; Colin C; Bachelot T; Jaisson-Hot I; Derain L; Magaud L; Fournel-Federico C; Mousseau M; Tigaud JD; Jacquin JP; Trillet-Lenoir V
    Am J Clin Oncol; 2009 Aug; 32(4):369-74. PubMed ID: 19381078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer].
    Martins SJ; Yamamoto CA
    Rev Assoc Med Bras (1992); 2008; 54(6):494-9. PubMed ID: 19197525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Vos EJ; Linn SC; Rodenhuis S
    Ned Tijdschr Geneeskd; 2006 Apr; 150(14):776-80. PubMed ID: 16649394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.